All Pharma News
XyloCor`s XC001 Positive EXACT Phase 2 Data Presented, Published

XyloCor`s XC001 Positive EXACT Phase 2 Data Presented, Published
BUSINESSWIRE
02 May 2024
Share Share
XyloCor Presents Phase 2 Data Highlighting Safety and Efficacy of XC001

XyloCor Presents Phase 2 Data Highlighting Safety and Efficacy of XC001
BUSINESSWIRE
25 Aug 2023
Share Share
Results from XyloCor’s Phase 1 Portion of EXACT Trial of XC001 Published

Results from XyloCor’s Phase 1 Portion of EXACT Trial of XC001 Published
BUSINESSWIRE
03 Aug 2023
Share Share
XyloCor Reports Sustained Results of Phase 2 EXACT Clinical Trial of XC001

XyloCor Reports Sustained Results of Phase 2 EXACT Clinical Trial of XC001
BUSINESSWIRE
18 Jul 2023
Share Share
XyloCor reports positive data from refractory angina gene therapy trial

XyloCor reports positive data from refractory angina gene therapy trial
CLINICAL TRIALS ARENA
27 Jan 2023
Share Share
XyloCor Reports Positive Safety Results from Phase 2 EXACT Trial of XC001

XyloCor Reports Positive Safety Results from Phase 2 EXACT Trial of XC001
BUSINESSWIRE
26 Jan 2023
Share Share
XyloCor gene therapy hits goals, paving way for pivotal trial

XyloCor gene therapy hits goals, paving way for pivotal trial
Gabrielle Masson FIERCE BIOTECH
26 Jan 2023
Share Share
XyloCor Achieves Target Enrollment in PII EXACT Study of XC001 Gene Therapy

XyloCor Achieves Target Enrollment in PII EXACT Study of XC001 Gene Therapy
BUSINESSWIRE
28 Jun 2022
Share Share
XyloCor to Present Prelim Clinical Data from PI Portion of PI/II Study of XC001

XyloCor to Present Prelim Clinical Data from PI Portion of PI/II Study of XC001
BUSINESSWIRE
18 May 2022
Share Share
XyloCor begins Phase II part of EXACT trial for refractory angina

XyloCor begins Phase II part of EXACT trial for refractory angina
CLINICAL TRIAL ARENA
28 Jul 2021
Share Share